CN86100411A - 生产噻唑烷二酮的方法 - Google Patents

生产噻唑烷二酮的方法 Download PDF

Info

Publication number
CN86100411A
CN86100411A CN86100411.6A CN86100411A CN86100411A CN 86100411 A CN86100411 A CN 86100411A CN 86100411 A CN86100411 A CN 86100411A CN 86100411 A CN86100411 A CN 86100411A
Authority
CN
China
Prior art keywords
compound
gram
pyridyl
ethyl
oxyethyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN86100411.6A
Other languages
English (en)
Other versions
CN1003934B (zh
Inventor
目黑宽同
藤田刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11683488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN86100411(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN86100411A publication Critical patent/CN86100411A/zh
Publication of CN1003934B publication Critical patent/CN1003934B/zh
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

式：

Description

本发明涉及新颖的噻唑烷二酮衍生物、制备这类衍生物以及用于医药领域的含有这类衍生物的抗糖尿病药剂的方法。
在临床上，使用各种双缩胍和磺酰尿衍生物作为抗糖尿病药剂。
但是，现在很少使用双缩胍类，因为双缩胍往往引起乳酸中毒;而且，虽然磺酰尿类具有很强的降血糖活性，但是使用磺酰尿类时，必须十分小心，因为它们往往造成严重的低血糖。因此，一直期待着一种新型的无这类缺点的抗糖尿病药剂。
在另一方面，在日本特许公开特开昭55-22636和特开昭55-64586以及“化学和药物公报”（Chemical    &    Pharmaceutical    Bulletion），30，第3563页（1982）;出处同上，30，第3580页（1982）和32，第2267页（1982）等文献中，提到了具有使血葡萄糖和血脂降低作用的各种噻唑烷二酮类。在“糖尿病”（Diabetes），32，第804页（1983）之中。也报道了西格利塔腙（Ciglitazone）的抗糖尿病活性。但是，这些化合物均未在实践中采用。可以提出的理由是：1）活性不足，或者/和2）有强毒性。
本发明人合成了各种在上面提到的日本特许公开说明书中未具体描述过的各种化合物，而且对其进行了研究，发现这些化合物具有潜在的药理作用，而且毒性较小。
本发明要提出一些在医疗上可以作为抗糖尿病药剂使用的化合物，这些化合物在药理作用和毒性或者不希望有的副反应之间具有很宽的安全范围。
本发明涉及：
1）（Ⅰ）式化合物
Figure 86100411_IMG4
或其药理上可接受的盐，
2）抗糖尿病药剂，其中含有（Ⅰ）式化合物或其药理上可接受的盐作为有效成分，以及
3）制备（Ⅰ）式化合物或其药理上可接受盐的方法，其中包括使下式化合物水解：
Figure 86100411_IMG5
用上面的（Ⅰ）式所表示的化合物，具体地说包括下列物质：
5-〔4-〔2-（3-乙基-2-吡啶基）乙氧基〕苄基〕-2，4-噻唑烷二酮，
5-〔4-〔2-（4-乙基-2-吡啶基）乙氧基〕苄基〕-2，4-噻唑烷二酮，
5-〔4-〔2-（5-乙基-2-吡啶基）乙氧基〕苄基〕-2，4-噻唑烷二酮，
5-〔4-〔2-（6-乙基-2-吡啶基）乙氧基〕苄基〕-2，4-噻唑烷二酮。
本发明的化合物（Ⅰ），在分子中既包含碱性氮也包含酸性氮，而且可以用适当的酸或碱在需要时使之转变成药理上可接受的盐。
这种酸的盐类，例如有无机酸盐（如盐酸盐、氢溴酸盐和硫酸盐等等）、有机酸盐（如丁二酸盐、顺丁烯二酸盐、反丁烯二酸盐、苹果酸盐和酒石酸盐等等）以及磺酸盐（例如甲磺酸盐、苯磺酸盐和甲苯磺酸盐等等）。这种碱的盐，例如有碱金属盐（如钠盐、钾盐）和碱土金属盐（如钙盐等），所有这些盐实际都用已知的方法制备。
本发明的（Ⅰ）式化合物或其药理上可接受的盐，具有降低血葡萄糖和血脂的作用，而且毒性较小;可以直接使用它们，或者以与业已知道的药理上可接受的载体、赋形剂或填料组成混合物的形式使用，以作为哺乳动物（包括人）的抗糖尿病药剂。
这种抗糖尿病药剂，通常以片剂、胶囊（包括软胶囊和微胶囊）剂、粉剂和粒剂等以进行口服投药，而且根据情况，也可以以注射液、栓剂和小丸片等形式进行非肠道投药。成年病人的口服药量最好为0.05-10mg/公斤体重/天，非肠道投药量为0.01-10mg/公斤体重/天，每天一次，或者每周分成2-4次。
由上面提到的通式（Ⅰ）所代表的化合物及其药理上可接受的盐（以下统称“化合物（Ⅰ）”），可由对（Ⅱ）式所代表的化合物进行水解的方法制备。这种水解反应，最好在适当溶剂中用无机酸的条件下进行。所用的溶剂例如有醇类（例如甲醇、乙醇、丙醇、丁醇、异丁醇和2-甲氧基乙醇等）、二甲基亚砜、二氧噻吩烷、二噁烷、四氢呋喃和二甲氧基乙烷等;所用的无机酸例如有盐酸、氢溴酸和硫酸等。水解反应的温度范围从20℃至150℃。反应时间为0.5-20小时。
所制备的上述通式为（Ⅰ）的化合物或其药理上可接受的盐可用传统的浓缩、萃取、重结晶、色层等方法进行分离和纯化。
由上面提到的通式（Ⅱ）所代表的化合物，可以通过下述反应制备：
〔其中R代表氢或者低级烷基〕。
由R所代表的低级烷基，例如是甲基、乙基、丙基、异丙基和丁基之类的C1-C4烷基。
由化合物（Ⅲ）和化合物（Ⅳ）制备化合物（Ⅴ）的反应，是在例如氢化钠存在下进行的。这个反应，可以在-10℃至30℃温度范围内，于某种溶剂中，例如在二甲基甲酰胺和四氢呋喃中进行。由化合物（Ⅴ）生成化合物（Ⅵ）的反应，很容易通过传统的催化还原。采用例如钯-碳作为催化剂来实现。可以以纯产物的形式分离化合物（Ⅵ），也可以使化合物（Ⅵ）在不分离、不提纯的条件下直接进行下一步反应。通过在氢溴酸水溶液存在下，使化合物（Ⅵ）进行重氮化，然后在铜催化剂存在下，例如氧化亚铜、氧化铜、氯化亚铜、氯化铜、溴化亚铜、溴化铜等存在下，使生成物与丙烯酸或者其低级烷基酯（Ⅶ）反应（米尔文芳基化作用，Meerwein    arylation），制备化合物（Ⅷ）。化合物（Ⅷ）可以用例如色谱法提纯，而且可以不经分离或者提纯直接进行随后的反应。
然后使化合物（Ⅷ）与硫脲反应生成化合物（Ⅱ）。这个反应通常是在醇类（例如甲醇、乙醇、丙醇、丁醇、异丁醇和α-甲氧基乙醇等）、二甲基亚砜和二氧噻吩烷等之中进行。反应温度通常为20-180℃，最好为60-150℃。所使用的硫脲量，相对于每摩尔化合物（Ⅷ）有1-2摩尔硫脲。
对于这个反应来说，在反应进行时，产生付产物溴化氢，因此为了捕获此付产物，可以在乙酸钠或乙酸钾等存在下进行此反应，其用量相对于每摩尔化合物（Ⅷ）为1-1.5摩尔。可以分离生成的化合物（Ⅱ），但是也可以不经分离直接进行水解。
本发明的化合物（Ⅰ），具有优良的使血葡萄糖和血脂降低的活性，而且毒性很低，这一点可用下列实验数据来证实。
实验例
1.小鼠体内血糖和血脂降低活性
将试验化合物（在三个剂量水平下）以CE-2粉末食物的规定食物混合物形式（CLEA日本）给雄性KKAy鼠（8-10周的鼠，每组5只）喂食，同时使之自由饮水四天。
在第五天，自鼠眼眶静脉中取出血样。
采用葡萄糖氧化酶法和使用在市场可买到的分析仪器Cleantech TG-S（Iatron，日本），分别测定血液葡萄糖和血浆甘油三酯（TG）。根据血液葡萄糖和血浆甘油三酯降低活性的剂量响应曲线，计算了每个试验化合物与对照值相比减小25%的有效剂量，作为ED25值（mg/公斤/天）。结果示于表1之中。
2.大鼠体内血脂降低活性
给雄性Sprague-Dawley大鼠（7周的大鼠，每组5只）供给实验室食物（日本，CLEA，CE-2），同时使之自由饮水。让这些鼠强制性经口投药这些试验化合物（三个剂量水平），四天投药的试验化合物均悬浮于5%的阿拉伯胶溶液中。在第五天，自大鼠尾静脉中取出血液样品。使用市场上可以买到的分析仪器Cleantech TG-S（Iatron）测定血浆甘油三酯。根据血脂降低活性的剂量响应曲线，计算了每个试验化合物的血脂减少与对照值相比为25%的有效剂量，作为ED25值（mg/公斤/天）。结果列于表1之中。
3.大鼠的两周毒性研究
给雄性和雌性Sprague-Dawley大鼠（五周的大鼠，每组五只）进食实验室食物（日本，CLEA，CE-2），同时使之自由饮水，给这些大鼠强制地经口投药试验化合物二周，每日一次，所有的试验化合物均悬浮于5%的阿拉伯胶溶液中。每个试验化合物的剂量为100mg/公斤/天。当两周投药结束后，在乙醚麻醉的条件下，使用经肝素化的注射器从腹主动脉中抽取血液样品，经过大约20小时禁食，杀死这些动物，切除肝脏和心脏，称重。使用自动细胞计数器进行血液分析。这些数据表示相对于对照值增加或者减少的%，正如表1中所示的那样。
在表1中，化合物（Ⅰ）是属于本发明范围内的一个化合物，而化合物（a）和（b）是在日本特许公开特开昭55-22636中具体提到的已知化合物。
虽然化合物（c）、（d）和（e）未在上面提到的专利申请中具体提过，但是也引证了以便于比较，因为这些化合物在其化学结构上与本发明的化合物（Ⅰ）类似。正如表1中给出的实验结果所表明的那样，本发明的化合物（Ⅰ）在降血糖和降血脂活性方面优于化合物（a）、（c）、（d）和（e），而与化合物（b）相当，和（a）、（b）、（c）、（d）和（e）化合物相比，其毒性极低。通过引入乙基所带来的上述效果完全出乎意料。因此，本发明的化合物（Ⅰ）表现有良好的降低血糖和低血脂活性，而且即使连续长时间投药的条件下对内部器官和血液的毒性均极小。所以化合物（Ⅰ）对于哺乳动物（包括人）的Ⅱ型糖尿病及其伴随的肥胖症和血脂过多症是有价值的治疗药剂。
实施例1
a）在冰冷却的条件下，将在油（16.0克）中的60%的氢化钠分批加入2-（5-乙基-2-吡啶基）乙醇（53.0克）和4-氟硝基苯（47.0克）的二甲基甲酰胺（500ml）溶液中，将此混合物在冰冷却的条件下搅拌1小时，然后在室温下搅拌30分钟，倒入水中，用乙醚萃取，用水洗涤乙醚层，经MgSO4干燥，蒸除溶剂，制得晶体状4-〔2-（5-乙基-2-吡啶基）乙氧基〕硝基苯（62.0克，产率62.9%），经乙醚-己烷重结晶后，制成无色的棱晶体，熔点53-54℃。
b）在10%Pd-c催化剂（50%湿品，6.0克）存在下，于室温和1大气压条件下，使溶解在甲醇（500ml）中的4-〔2-（5-乙基-2-吡啶基）乙氧基〕硝基苯（60.0克）的溶液氢化，过滤除去催化剂，在减压下浓缩滤液，将残留的油状物溶解在丙酮（500ml）-甲醇（200ml）之中，在此溶液中加入47%的HBγ水溶液（152克），冷却此混合物，在不高于5℃条件下，在此混合物中滴加NaNO2（17.3克）的水（30ml）溶液，5℃下将此全部混合物搅拌20分钟，然后在其中加入丙烯酸甲酯（112克），使温度提高到38℃，剧烈搅拌下，在此混合物中逐渐加入氧化亚铜（2.0克）。搅拌此混合物直至停止产生氮气为止，在减压下加以浓缩，用浓氨水碱化此浓集物，用乙酸乙酯萃取，乙酸乙酯层用水洗涤，干燥（MgSO4）。蒸发除去溶剂，残留下2-溴-3-｛4-〔2-（5-乙基-2-吡啶基）乙氧基〕苯基｝丙酸甲酯，呈原油状物（74.09克，85.7%）。红外光谱（净）Cm-1：1735。核磁共振δ（PPm）（在CDCl3中）：1.21（3H，t，J＝7），2.60（2H，q，J＝7），3.0-3.6（4H，m），3.66（3H，S），4.30（2H，t，J＝7），4.3（1H，m），6.7-7.5（6H，m），8.35（1H，d，J＝2）。
c）将在b）中得到的2-溴-3-｛4-〔2-（5-乙基-2-吡啶基）乙氧基〕苯基｝丙酸甲酯（73.0克）、硫脲（14.2克）、乙酸钠（15.3克）和乙醇（500ml）的混合物，迴流下搅拌3小时，减压下浓缩此反应混合物，用碳酸氢钠饱和水溶液中和得到的浓集物，在其中加入水（200ml）和乙醚（100ml）。将全部混合物搅拌10分钟，生成5-｛4-〔2-（5-乙基-2-吡啶基）乙氧基〕苯基｝-2-亚胺基-4-噻唑烷二酮晶体（0.3克，523.0%）。经甲醇重结晶后，得到无色棱晶体，熔点187-188℃（分解）。C19H21N3O2S的元素分析结果：
计算值：C，64.20;H，5.95;N，11.82。
测得值：C，64.20;H，5.84;N，11.73。
d）将5-｛4-〔2-（5-乙基-2-吡啶基）乙氧基〕苄基｝-2-亚胺基-4-噻唑烷二酮（23.5克）的2NHCl（200ml）溶液迴流6小时。减压下蒸除溶剂，用碳酸氢钠饱和水溶液中和此残余物。过滤收集沉淀出的晶体（23.5克，97.5%），用二甲基甲酰胺-水重结晶，制得无色针状的5-｛4-〔2-（5-乙基-2-吡啶基）乙氧基〕苄基｝-2，4-噻唑烷二酮（20.5克，86.9%），熔点为183-184℃。C19H20N2O3S的元素分析结果：
计算值：C，64.02;H，5.66;N，7.86。
测得值：C，63.70;H，5.88;N，8.01。
e）在5-｛4-〔2-（5-乙基-2-吡啶基）乙氧基〕苄基｝-2，4-噻唑烷二酮（356mg）的甲醇（10ml）的悬浮液中，加入28%甲醇钠-甲醇溶液（0.2克）以制备溶液。浓缩此溶液，用乙醚稀释至生成晶体。过滤收集这些晶体，用甲醇-乙醇重结晶，制成5-｛4-〔2-（5-乙基-2-吡啶基）乙氧基〕苄基｝-2，4-噻唑烷二酮的钠盐，是无色晶体（298mg，78.8%），熔点262-263℃（分解）。
C19H19N2O3SNa的元素分析结果：
计算值：C，60.31;H，5.06;N，7.40。
测得值：C，60.20;H，5.07;N，7.52。
实施例2
（1）5-｛4-〔2-（5-乙基-2-吡啶基）乙氧基〕苄基｝-2，4-噻唑烷二酮    100克
（2）乳糖    50克
（3）谷物淀粉    15克
（4）羧甲基纤维素钙    44克
（5）硬脂酸镁    1克
共计    210克
将（1）、（2）和（3）的总量及30克（4），用水捏和，真空干燥，然后造粒。使14克（4）和1克（5）与制得的粒状物混合，使用制片机将全部混合物制片，制得直径为8mm的药片1000片，每片含100mg（1）。
参照例1
按照实施例1-a）的步骤，制备表2中列出的化合物。
Figure 86100411_IMG8
参照例2
按照实施例1-b）制备下列化合物。
2-溴-3-｛4-〔2-（4-甲基-2-吡啶基）乙氧基〕苯基｝丙酸甲酯。红外光谱（净）Cm-1：1735。核磁共振δ（PPm，CDCl3）：2.34（3H，S），3.10（1H，dd，J＝14和7），3.25（2H，t，J＝6），3.38（1H，dd，J＝14和7），3.67（3H，S），4.29（1H，t，J＝7），4.37（2H，t，J＝6），6.8-7.5（6H，m），8.35（1H，dd，J＝5和2）。
2-溴-3-｛4-〔2-（4-甲基-2-吡啶基）乙氧基〕苯基｝-丙酸甲酯。红外光谱（净）Cm-1：1735。核磁共振δ（PPm，CDCl3）：2.30（3H，S），3.10（1H，dd，J＝14和7），3.26（3H，t，J＝7），3.37（1H，dd，J＝14和7），3.67（3H，S），4.30（3H，t，J＝7），67-7.36（6H，m），8.37（1H，d，J＝6）。
参照例3
在10%Pd-c催化剂（50%湿品，2.0克）存在下，1大气压下使溶有4-〔2-（5-甲基-2-吡啶基）乙氧基〕硝基苯（15.0克）的甲醇（150ml）溶液催化还原，滤除催化剂，浓缩滤液制得4-〔2-（5-甲基-2-吡啶基）乙氧基〕苯胺晶体（12.3克，92.5%），用乙酸乙酯-己烷重结晶，制得无色棱晶体，熔点74-75℃。
C14H16H2O的元素分析。
计算值：C，73.66;H，7.06;N，12.27。
测得值：C，73.84;H，7.17;N，12.06。
参照例4
在4-〔2-（5-甲基-2-吡啶基）乙氧基〕苯胺（12.0克）、47%的HBr水溶液（36.5克）和甲醇（40ml）-丙酮（80ml）的混合物中，在5℃或低于5℃下滴加NaNO2（4.0克）水（10ml）溶液。5℃下将全部混合物搅拌20分钟，然后在其中加入丙烯酸甲酯（27.0克），将温度提高到38℃。剧烈搅拌下，逐渐在此混合物中加入氧化亚铜（1.0克），停止产生氮气后，在减压下浓缩此反应混合物，用浓氨水碱化此浓集物，然后用乙酸乙酯萃取，用水洗涤乙酸乙酯层，干燥（MgSO4），蒸除溶剂后，残留下2-溴-3-｛4-〔2-（5-甲基-2-吡啶基）乙氧基〕苯基｝-丙酸甲酯（17.5克，87.5%），呈原油状物。红外光谱（净）Cm-1：1735。核磁共振δ（PPm，CDCl3）：2.27（3H，S），3.10（1H，dd，J＝14和7），3.22（2H，t，J＝6），3.38（1H，dd，J＝14和7），3.66（3H，S），4.29（2H，t，J＝6），4.32（1H，t，J＝7），6.7-7.5（6H，m），8.34（1H，d，J＝2）。
参照例5
按照实施例1-c）制备表3所列的化合物
Figure 86100411_IMG9
Figure 86100411_IMG10
参照例6
按照实施例1-d）制备表4中所列的化合物。
参照例7
将2-亚胺基-5-｛4-〔2-（5-甲基-2-吡啶基）乙氧基〕苄基｝-4-噻唑烷二酮（8.0克）、2NHCl（80ml）和乙醇（80ml）的混合物迴流16小时。用碳酸氢钠饱和水溶液中和此反应溶液以生成晶体，过滤收集这些晶体，用乙醇重结晶后得出5-｛4-〔2-（5-甲基-2-吡啶基）乙氧基〕苄基｝-2.4-噻唑烷二酮（7.0克，87.5%），为无色棱晶体，熔点192-193℃。
C18H18N2O3的元素分析：
计算值：C，63.14;H，5.30;N，8.18。
测得值：C，63.22;H，5.40;N，8.11。

Claims (1)

1、一种制备式为
的化合物或其药理上可接受盐的方法，其特征在于使式为
Figure 86100411_IMG3
的化合物水解。
CN86100411.6A 1985-01-19 1986-01-18 生产噻唑烷二酮的方法 Expired CN1003934B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8085/1985 1985-01-19
JP808585 1985-01-19

Publications (2)

Publication Number Publication Date
CN86100411A true CN86100411A (zh) 1986-07-16
CN1003934B CN1003934B (zh) 1989-04-19

Family

ID=11683488

Family Applications (1)

Application Number Title Priority Date Filing Date
CN86100411.6A Expired CN1003934B (zh) 1985-01-19 1986-01-18 生产噻唑烷二酮的方法

Country Status (28)

Country Link
US (1) US4687777A (zh)
EP (1) EP0193256B1 (zh)
JP (1) JPS61267580A (zh)
KR (1) KR920010046B1 (zh)
CN (1) CN1003934B (zh)
AR (1) AR240698A1 (zh)
AT (1) ATE41931T1 (zh)
AU (1) AU572719B2 (zh)
BR (1) BR1100325A (zh)
CA (1) CA1277323C (zh)
CS (1) CS407991A3 (zh)
DE (2) DE3662689D1 (zh)
DK (2) DK21986A (zh)
ES (1) ES8705886A1 (zh)
FI (1) FI81098C (zh)
GR (1) GR860124B (zh)
HK (1) HK3692A (zh)
HU (1) HU196795B (zh)
IE (1) IE58928B1 (zh)
LU (1) LU90719I2 (zh)
LV (1) LV5779B4 (zh)
MX (1) MX9202933A (zh)
MY (1) MY102016A (zh)
NL (1) NL300038I2 (zh)
NO (1) NO163857C (zh)
PT (1) PT81859B (zh)
SG (1) SG105691G (zh)
ZA (1) ZA86203B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
CN102149669A (zh) * 2008-10-10 2011-08-10 株式会社德山 羰氧基化合物的制备方法
CN101222912B (zh) * 2005-03-30 2012-10-03 华生制药公司 包含双胍和噻唑烷二酮衍生物的药物新剂型

Families Citing this family (268)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK305884A (da) * 1983-06-24 1984-12-25 Yamanouchi Pharma Co Ltd Phenoxyderivat, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4968707A (en) * 1987-06-10 1990-11-06 Pfizer Inc. Oxazolidin-2-one derivatives as hypoglycemic agents
GB8713861D0 (en) * 1987-06-13 1987-07-15 Beecham Group Plc Compounds
EP0295828A1 (en) * 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US4798835A (en) * 1987-12-02 1989-01-17 Pfizer Inc. dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US4997948A (en) * 1989-10-27 1991-03-05 American Home Products 5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
CA2071629C (en) * 1990-02-09 1997-12-30 Jerry R. Colca Use of insulin sensitizing agents to treat hypertension
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
ATE205206T1 (de) * 1990-04-27 2001-09-15 Sankyo Co Benzylidenthiazolidinderivate, ihre herstellung und ihre anwendung als lipidperoxid-inhibitoren
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
DK0579733T3 (da) * 1991-04-11 2001-10-15 Upjohn Co Thiazolidindionderivater, fremstilling og anvendelse deraf
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
NZ274346A (en) * 1993-09-15 1997-06-24 Sankyo Co Use of various thiazolidine-2,4-dione and oxazolidine-2,4-dione derivatives to prevent or delay onset of non-insulin dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
WO1995024400A1 (en) * 1994-03-08 1995-09-14 American Home Products Corporation Thiazolidinedione derivatives as anti-hyperglycemic agents
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
RU2137770C1 (ru) * 1994-10-20 1999-09-20 Ниппон Кемифар Ко., Лтд. Производные хинолина
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
AU5121796A (en) * 1995-05-08 1996-11-29 Nippon Chemiphar Co. Ltd. 2,4-thiazolidinedione or oxazolidinedione derivatives and hy poglycemic agent
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
TW474809B (en) * 1995-07-03 2002-02-01 Sankyo Co A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
JP2000511883A (ja) * 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
DE69738809D1 (de) * 1996-11-08 2008-08-14 Nippon Chemiphar Co Mittel zur verringerung der eigeweidefette
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
WO1999030739A1 (fr) * 1997-12-16 1999-06-24 Sankyo Company, Limited Remede contre la leucemie
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AU4314000A (en) 1999-04-28 2000-11-17 Institute Of Medicinal Molecular Design. Inc. Heterocyclic carboxylic acid derivatives
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
CN1321153A (zh) * 1999-07-01 2001-11-07 杰龙公司 端粒酶抑制剂及其使用方法
US7390824B1 (en) * 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
ES2156574B1 (es) * 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
NZ519592A (en) 1999-12-03 2003-11-28 Kyoto Pharma Ind Novel heterocyclic compounds and salts thereof and medicinal use of the same
AU2001237321A1 (en) 2000-01-21 2001-07-31 Novartis Ag Combinations comprising dipeptidylpeptidase - iv inhibitor
US6958355B2 (en) * 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
MXPA02010545A (es) * 2000-04-25 2004-05-14 Kyorin Seiyaku Kk Cristal estable novedoso de derivado de tiazolidinediona y proceso para producir el mismo.
AU2001294673A1 (en) * 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
EP1354602B1 (en) * 2000-12-26 2006-10-04 Sankyo Company, Limited Medicinal compositions containing diuretic and insulin resistance-improving agent
CA2434436A1 (en) * 2001-01-26 2002-08-01 Teddy Kosoglou Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
AU2002240050A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
ATE381347T1 (de) * 2001-01-26 2008-01-15 Schering Corp Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
RS50406B (sr) * 2001-01-26 2009-12-31 Schering Corporation, Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
CA2434033A1 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CN100408579C (zh) * 2001-02-24 2008-08-06 贝林格尔英格海姆法玛两合公司 黄嘌呤衍生物,其制法及其作为药物组合物的用途
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
CN100577175C (zh) * 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
CA2445322C (en) * 2001-04-25 2011-06-14 Takeda Chemical Industries, Ltd. Use of the abc expression promoting agent pioglitazone for the treatment of arteriosclerosis obliterans
PL363738A1 (en) * 2001-04-26 2004-11-29 Leciva A.S. Method for obtaining pioglitazone as an antidiabetic agent
HUP0401862A3 (en) * 2001-05-29 2009-03-30 Kyoto Pharmaceutical Ind Novel heterocyclic compound and medicinal use thereof and pharmaceutical compositions containing them
JP4279137B2 (ja) * 2001-05-29 2009-06-17 京都薬品工業株式会社 新規複素環誘導体およびその医薬用途
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
PT1427409E (pt) * 2001-09-21 2008-11-27 Schering Corp Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
WO2003026643A2 (en) * 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7135485B2 (en) * 2001-09-28 2006-11-14 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
IL162460A0 (en) * 2001-12-20 2005-11-20 Teva Pharma Hydrogenation of precursors to thiazolidinedione antihyperglycemics
US20050187258A1 (en) * 2001-12-20 2005-08-25 Ben-Zion Dolitzky Hydrogenation of precursors to thiazolidinedione antihyperglycemics
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
US20050084840A1 (en) * 2002-01-23 2005-04-21 Hideki Endoh Method for screening drug for improving insulin resistance
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
AU2003272072A1 (en) 2002-07-16 2004-02-02 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004024059A2 (en) * 2002-09-12 2004-03-25 Themis Laboratories Private Limited, Improved process for preparation of thiazolidinedione derivatives
CN100544717C (zh) 2002-09-20 2009-09-30 华生制药公司 含有双胍和噻唑烷二酮衍生物的药物剂型
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
AU2003291719A1 (en) * 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
JP5137228B2 (ja) * 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
WO2004108721A1 (en) * 2003-04-01 2004-12-16 Sun Pharmaceutical Industries Limited Process for the preparation of 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methyl]-2,4-thiazolidinedione
ES2219180B1 (es) * 2003-05-09 2006-03-01 Medichem, S.A. Compuesto intermedio util para la preparacion de pioglitazona.
JP2007502847A (ja) * 2003-05-13 2007-02-15 シントン・ベスローテン・フェンノートシャップ チアゾリジンジオン誘導体およびその化合物を製造する方法
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
SI1622899T1 (sl) * 2003-05-13 2007-10-31 Synthon Bv Pioglitazonsulfat, farmacevtski sestavki in njihova uporaba
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
JPWO2004106542A1 (ja) * 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
EP2319843B1 (en) 2003-05-30 2013-04-03 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as HMG-CO inhibitors
CN1867560A (zh) 2003-08-13 2006-11-22 武田药品工株式会社 4－嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途
WO2005021542A2 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Process for the preparation of pioglitazone
AU2003269479A1 (en) * 2003-09-03 2005-03-16 Biocon Limited Phosphoric acid salt of 5-((4-(2-(5-ethyl-2-pyridinyl) ethoxy) phenyl) methyl)-2, 4-thiazolidinedione
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
WO2005027967A1 (ja) * 2003-09-17 2005-03-31 Kaname Kawasugi 医薬組成物
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2005080387A2 (en) * 2004-02-20 2005-09-01 Synthon B.V. Processes for making pioglitazone and compounds of the processes
CN102134231B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
KR20070011329A (ko) * 2004-03-29 2007-01-24 상꾜 가부시키가이샤 인슐린 저항성 개선제를 함유하는 당뇨병 치료제
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
US20060025478A1 (en) * 2004-07-27 2006-02-02 Keisuke Inoue Medicine for prevention or treatment of diabetes
TW200608967A (en) * 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
JP4854511B2 (ja) * 2004-08-26 2012-01-18 武田薬品工業株式会社 糖尿病治療剤
WO2006035459A1 (en) * 2004-09-28 2006-04-06 Morepen Laboratories Limited An improved process for the production of derivatives of thiozolidinediones and their precursors
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
NZ560269A (en) * 2005-03-08 2010-12-24 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
US20080319031A1 (en) * 2005-03-18 2008-12-25 Orchid Chemicals & Pharmaceuticals Limited Novel Tyrosine Derivatives
WO2006117654A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Processes for the preparation of pioglitazone or salts thereof
WO2007007757A1 (ja) * 2005-07-12 2007-01-18 Daiichi Sankyo Company, Limited PPARγアゴニストを含有する医薬組成物
WO2007029062A2 (en) * 2005-07-29 2007-03-15 Orchid Research Laboratories Limited Novel pyridine derivatives
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EA015169B1 (ru) * 2005-09-14 2011-06-30 Такеда Фармасьютикал Компани Лимитед Применение ингибиторов дипептидилпептидазы
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
TW200730173A (en) * 2005-12-16 2007-08-16 Sankyo Co Pharmaceutical composition enhancing production of adiponectin
JP5269758B2 (ja) * 2006-03-16 2013-08-21 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 代謝性炎症によって媒介される疾患を処置するためのチアゾリジンジオン類似体
MX2008011872A (es) * 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
CA2646170A1 (en) * 2006-03-16 2007-09-27 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
EA015687B1 (ru) 2006-05-04 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Полиморфы
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
KR100791399B1 (ko) 2006-09-06 2008-01-07 동우신테크 주식회사 염산 피오글리타존의 제조방법
UA100497C2 (ru) 2006-09-07 2013-01-10 Никомед Гмбх Комбинированное лечение сахарного диабета
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
RU2009126633A (ru) * 2006-12-13 2011-01-20 Джилид Сайэнс, Инк. (US) Монофосфатные соединения, способ их получения, аэрозольный препарат (варианты) и способ профилактики и/или лечения бронхостеноза посредством указанных соединений
WO2008075380A2 (en) * 2006-12-21 2008-06-26 Ind-Swift Laboratories Limited Process for the preparation of thiazolidine derivatives
WO2008091624A2 (en) * 2007-01-22 2008-07-31 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
MY147596A (en) * 2007-02-01 2012-12-31 Takeda Pharmaceutical Solid preparation comprising alogliptin and pioglitazone
US8242151B2 (en) 2007-02-07 2012-08-14 Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds
WO2008105326A1 (ja) * 2007-02-28 2008-09-04 Ohara Chemical Industries, Ltd. ２－イミノ－４－チアゾリジノン誘導体及び２，４－チアゾリジンジオン誘導体の製造方法
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
EP3053440B1 (en) 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
KR101560844B1 (ko) 2007-06-04 2015-10-15 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 트라이-아릴계 화합물 및 이를 포함하는 조성물
PT2489731E (pt) 2007-07-26 2014-09-15 Amgen Inc Enzimas aciltransferase de lecitina-colesterol modificadas
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
JP5371988B2 (ja) 2007-09-14 2013-12-18 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 高血圧を処置するためのチアゾリジンジオン類似体
WO2009035997A2 (en) * 2007-09-14 2009-03-19 Cara Therapeutics, Inc. Benzo-fused heterocycles
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20090118514A1 (en) * 2007-11-06 2009-05-07 Raghupathi Reddy Anumula Processes for preparing pioglitazone and its pharmaceutically acceptable salts
JP5334422B2 (ja) * 2008-02-13 2013-11-06 株式会社トクヤマ ５−｛４−［２−（５−エチル−２−ピリジル）エトキシ］ベンジル｝−２−イミノ−４−チアゾリジノンの製造方法
JP5197063B2 (ja) * 2008-02-21 2013-05-15 株式会社トクヤマ ２−ブロモ−３−｛４−［２−（５−エチル−２−ピリジル）エトキシ］フェニル｝プロピオン酸メチルの製造方法
AR071175A1 (es) * 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
US20110046382A1 (en) * 2008-04-28 2011-02-24 Erregierre S.P.A. Process for the preparation of 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene and pioglitazone
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP5559689B2 (ja) 2008-08-06 2014-07-23 協和発酵キリン株式会社 ３環系化合物
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CN104805198B (zh) * 2008-08-12 2019-04-26 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN103816158A (zh) * 2008-08-15 2014-05-28 勃林格殷格翰国际有限公司 用于治疗fab-相关疾病的嘌呤衍生物
JP5553759B2 (ja) * 2008-09-02 2014-07-16 株式会社トクヤマ 脱臭化水素化抑制剤
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP5473303B2 (ja) * 2008-12-01 2014-04-16 株式会社トクヤマ ２−ブロモ−３−｛４−［２−（５−エチル−２−ピリジル）エトキシ］フェニル｝プロピオン酸メチルの製造方法
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20110110766A (ko) * 2009-01-20 2011-10-07 가부시끼가이샤 도꾸야마 2-브로모-3-｛4-［2-（5-에틸-2-피리딜）에톡시］페닐｝프로피온산메틸의 탈브롬화 수소화를 억제하는 방법
JP2010208957A (ja) * 2009-03-06 2010-09-24 Tokuyama Corp 結晶構造を有する５−｛４−［２−（５−エチル−２−ピリジル）エトキシ］ベンジル｝−２−イミノ−４−チアゾリジノン及びその製造方法
CA2754901A1 (en) 2009-03-11 2010-09-16 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
NZ597108A (en) * 2009-06-25 2014-04-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds
ES2639065T5 (es) 2009-06-25 2023-01-30 Alkermes Pharma Ireland Ltd Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
KR101701943B1 (ko) 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX2012006725A (es) 2009-12-15 2012-06-28 Metabolic Solutions Dev Co Llc Sales de tiazolidinadiona reductoras de receptores activados por proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
AU2011207210A1 (en) 2010-01-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
EP2611434A1 (en) 2010-09-01 2013-07-10 Lupin Limited Pharmaceutical composition comprising metformin and pioglitazone
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
UA114704C2 (uk) 2011-01-10 2017-07-25 Зінфандел Фармасьютікалз, Інк. Способи та лікарські засоби для лікування хвороби альцгеймера
WO2012153312A1 (en) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Process for the purification of pioglitazone
EP2731947B1 (en) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
CN103874697A (zh) 2011-08-03 2014-06-18 协和发酵麒麟株式会社 二苯并氧杂*衍生物
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2638898A1 (en) 2012-03-16 2013-09-18 Sanovel Ilac Sanayi ve Ticaret A.S. Metformin and Pioglitazone Formulation with Different Release Profiles
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6453224B2 (ja) 2012-11-05 2019-01-16 コミッサリア ア レネルジ アトミック エ オー エネルジス アルテルナティヴスＣｏｍｍｉｓｓａｒｉａｔ Ａ Ｌ‘Ｅｎｅｒｇｉｅ Ａｔｏｍｉｑｕｅ Ｅｔ Ａｕｘ Ｅｎｅｒｇｉｅｓ Ａｌｔｅｒｎａｔｉｖｅｓ インビボで血液がんの幹細胞を排除するため、および血液がんの再発を防ぐための、チロシンキナーゼ阻害剤のような抗がん剤と、好ましくはチアゾリジンジオンであるｓｔａｔ５アンタゴニストとの組み合わせ
EP2968298B1 (en) 2013-03-14 2018-01-31 Deuterx, LLC Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014150512A1 (en) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Method and products for treating diabetes
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
US9815777B2 (en) 2013-09-22 2017-11-14 Jiva Pharma, Inc. Metformin salts to treat Type2 diabetes
CA2926685A1 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
KR20160094956A (ko) 2013-11-05 2016-08-10 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 당뇨병 및 당뇨병으로부터 발생하는 합병증 질환의 치료를 위한 화합물
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
KR101606547B1 (ko) * 2014-06-02 2016-03-28 김동연 공항 탑승객 위치조회시스템
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
MA39929A (fr) 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret As Comprimé multicouche comprenant de la metformine et du pioglitazone
WO2017211830A1 (en) 2016-06-08 2017-12-14 Support-Venture Gmbh Pharmaceutical combinations for treating cancer
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
EP3500258A1 (en) 2016-08-17 2019-06-26 Support-Venture GmbH Method of preventing or treating hearing loss
TR201620309A2 (tr) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
WO2018185098A1 (en) 2017-04-04 2018-10-11 Strekin Ag Methods of preventing or treating ophthalmic diseases
WO2019154893A1 (en) 2018-02-08 2019-08-15 Strekin Ag Oral extended release pharmaceutical compositions for preventing or treating hearing loss
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
KR20210031909A (ko) 2018-07-13 2021-03-23 키나루스 아게 섬유증 질환을 예방 또는 치료하기 위한 ppar 효능제 및 p38 키나제 억제제의 조합물
CN111875598B (zh) * 2020-05-23 2023-10-10 白银京宇新药业有限公司 一种吡格亚胺的制备方法
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
EP4196120A1 (en) 2020-08-11 2023-06-21 Kinarus AG Methods of preventing or treating covid-19 and related viral diseases or disorders
AU2021354823A1 (en) 2020-09-30 2023-03-30 Duality Biologics (Suzhou) Co., Ltd. Antitumor compound, and preparation method therefor and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
US4898947A (en) * 1986-07-24 1990-02-06 Takeda Chemical Industries, Ltd. Pyridine and thiazolidinedione derivatives
USRE36575E (en) * 1986-07-24 2000-02-15 Takeda Chemical Industries, Ltd. Pyridine and thiazolidinedione derivatives
CN101222912B (zh) * 2005-03-30 2012-10-03 华生制药公司 包含双胍和噻唑烷二酮衍生物的药物新剂型
CN102149669A (zh) * 2008-10-10 2011-08-10 株式会社德山 羰氧基化合物的制备方法

Also Published As

Publication number Publication date
CN1003934B (zh) 1989-04-19
ATE41931T1 (de) 1989-04-15
JPH0566956B2 (zh) 1993-09-22
CS407991A3 (en) 1992-04-15
NO163857C (no) 1990-08-01
LV5779B4 (lv) 1997-04-20
DK21986A (da) 1986-07-20
HUT41775A (en) 1987-05-28
FI81098B (fi) 1990-05-31
FI81098C (fi) 1990-09-10
HK3692A (en) 1992-01-17
ZA86203B (en) 1987-09-30
PT81859A (en) 1986-02-01
MX9202933A (es) 1992-06-30
IE860107L (en) 1986-07-19
NO163857B (no) 1990-04-23
FI860232A0 (fi) 1986-01-17
LU90719I2 (fr) 2001-03-26
MY102016A (en) 1992-02-29
PT81859B (pt) 1988-05-27
EP0193256A1 (en) 1986-09-03
SG105691G (en) 1992-02-14
JPS61267580A (ja) 1986-11-27
DE3662689D1 (en) 1989-05-11
AU5246786A (en) 1986-07-24
NO860141L (no) 1986-07-21
HU196795B (en) 1989-01-30
ES8705886A1 (es) 1987-05-16
GR860124B (en) 1986-05-19
KR860005811A (ko) 1986-08-13
US4687777A (en) 1987-08-18
DK21986D0 (da) 1986-01-17
EP0193256B1 (en) 1989-04-05
ES550986A0 (es) 1987-05-16
FI860232A (fi) 1986-07-20
IE58928B1 (en) 1993-12-01
CA1277323C (en) 1990-12-04
BR1100325A (pt) 2000-06-27
LV5779A4 (lv) 1996-12-20
DE10199018I1 (de) 2001-07-12
AU572719B2 (en) 1988-05-12
KR920010046B1 (ko) 1992-11-13
NL300038I2 (nl) 2001-05-01
AR240698A1 (es) 1990-09-28
DK171614B1 (da) 1997-02-24
DE10199018I2 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
CN86100411A (zh) 生产噻唑烷二酮的方法
CN1040323C (zh) 噻唑烷衍生物
KR920002131B1 (ko) 타아졸리딘디온 유도체의 제조방법
EP0542816A1 (en) Oxazolidine dione derivatives
CN105358145A (zh) 协同组合物
CN1845917A (zh) 3－[(2－{[4－(已氧基羰基氨基－亚氨基－甲基)－苯氨基]－甲基}－1－甲基－1 h－苯并咪唑－5－羰基)－吡啶－2－基－氨基]－丙酸乙酯－甲磺酸酯及其作为药物的用途
EP0356214A2 (en) Thiazolidine dione derivatives
CN1167702C (zh) 5-[4-[2-n-甲基-n-(2-吡啶基)氨基]乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的多晶型物
EP0555264A1 (en) Novel compounds
CN1152304A (zh) 经取代的苄脒，其制备及作为药物化合物的用途
CN1019911C (zh) 新的苯并嗪衍生物的制备方法
WO2021196949A1 (zh) 一种glp-1受体激动剂的晶型a及其制备方法
FR2580642A1 (fr) 5-pyrimidinecarboxamides et traitement de la leucemie et des tumeurs en les utilisant
FR2480286A1 (fr) Nouveaux derives de theophyllinylmethyldioxolane, leurs procedes de preparation et leur application en therapeutique
JPS63174926A (ja) 家禽用抗コクシジウム剤
JPS61122212A (ja) 新規血糖降下剤
CN85101435A (zh) 新型化合物n，n′-甲撑-双(2氨基-5巯基-1，3，4噻二唑)制备方法及含此化合物的防治植物细菌性，病害杀菌剂
CN1594307A (zh) 野葛花中尼泊尔鸢尾异黄酮的提取分离及其磺化物制备方法和药物用途
CN1056369C (zh) 哒嗪酮衍生物或其盐和制备方法
EP0101380A2 (fr) Nicotinamide 1-oxyde N-substitué, ses sels, procédé pour leur préparation et compositions pharmaceutiques en contenant
CN1027893C (zh) 制备新的1，2-二硫杂环戊烯-3-硫酮-s-氧化物的方法
CN106279139A (zh) 可用作sglt2抑制剂的化合物及其制备方法和用途
CN1177846C (zh) 噁二唑基哒嗪酮衍生物及其制备方法与应用
CN100345846C (zh) 5－[4－[2－(n－甲基－n－(2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的钠盐
RU2136663C1 (ru) 5-гидроксиникотинат магния, обладающий комплексным антидиабетическим действием

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C13 Decision
GR02 Examined patent application
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term